Search results
Showing 46 to 60 of 103 results for autologous
Brexucabtagene autoleucel for treating relapsed or refractory mantle cell lymphoma (TA677)
Evidence-based recommendations on brexucabtagene autoleucel for treating relapsed or refractory mantle cell lymphoma in adults who have previously had a Bruton’s tyrosine kinase (BTK) inhibitor.
Obinutuzumab with bendamustine for treating follicular lymphoma after rituximab (TA629)
Evidence-based recommendations on obinutuzumab (Gazyvaro) with bendamustine for follicular lymphoma that has not responded or has progressed up to 6 months after treatment with rituximab or a rituximab-containing regimen in adults.
Awaiting development Reference number: GID-TA11846 Expected publication date: TBC
Aortic valve reconstruction with processed bovine pericardium (HTG461)
Evidence-based recommendations on aortic valve reconstruction with processed bovine pericardium. This involves replacing a damaged aortic valve with a new valve made from chemically treated cow pericardium.
View recommendations for HTG461Show all sections
Awaiting development Reference number: GID-TA11465 Expected publication date: TBC
Allogeneic pancreatic islet cell transplantation for type 1 diabetes mellitus (HTG165)
Evidence-based recommendations on allogeneic pancreatic islet cell transplantation for type 1 diabetes mellitus. This involves removing cells called islet cells, which are responsible for the production of insulin, from human donors.
View recommendations for HTG165Show all sections
Sections for HTG165
Evidence-based recommendations on glofitamab (Columvi) plus gemcitabine and oxaliplatin for treating relapsed or refractory diffuse large B-cell lymphoma not otherwise specified in adults.
Evidence-based recommendations on epcoritamab (Tepkinly) for treating relapsed or refractory diffuse large B-cell lymphoma in adults after 2 or more systemic treatments.
Atidarsagene autotemcel for treating metachromatic leukodystrophy (HST18)
Evidence-based recommendations on atidarsagene autotemcel (Libmeldy) for treating metachromatic leukodystrophy in children.
NICE has developed a medtech innovation briefing (MIB) on Hemosep for cell salvage .
Processed nerve allografts to repair peripheral nerve discontinuities (HTG454)
Evidence-based recommendations on processed nerve allografts to repair peripheral nerve discontinuities. This involves using a specially treated nerve (an allograft) taken from a human donor after death to bridge the gap in the nerve.
Autologous haematopoietic stem cell transplantation for treating multiple sclerosis [ID1111]
Discontinued Reference number: GID-TA10306
Focal resurfacing implants to treat articular cartilage damage in the knee (HTG635)
Evidence-based recommendations on focal resurfacing implants to treat articular cartilage damage in the knee in adults. This involves replacing the damaged area with an artificial implant.
View recommendations for HTG635Show all sections
Evidence-based recommendations on tissue-cultured limbal stem cell allograft transplantation for regrowth of corneal epithelium. This involves taking limbal stem cells from a living or deceased donor, growing them in the laboratory and transplanting them onto the patient’s affected eye(s).
View recommendations for HTG139Show all sections
Sections for HTG139
Endoscopic saphenous vein harvest for coronary artery bypass grafting (HTG342)
Evidence-based recommendations on endoscopic saphenous vein harvest for coronary artery bypass grafting. This involves removing the vein under endoscopic guidance through a small cut near the knee (keyhole surgery).